Translational Psychiatry

Translational Psychiatry (commonly abbreviated as Transl. Psychiatry) is a translational psychiatry title in the Nature Portfolio of Springer Nature, launched in April 2011. Fully open access and carrying only the electronic serial number 2158-3188, it exists to drive biological discovery about psychiatric disorders into clinical application and is among the most widely read open access journals in its field.《转化精神病学》（Translational Psychiatry，常用缩写为 Transl. Psychiatry）是 Springer Nature 旗下 Nature Portfolio 的转化精神病学刊物，2011 年 4 月创刊，完全开放获取，仅有电子刊号 2158-3188。该刊以推动精神疾病的生物学发现进入临床应用为宗旨，是这一领域传播量级最大的开放获取刊物之一。

Scope

The journal's editorial stance is translation as the measure of fit, requiring that papers examine psychiatric disorders directly and carry biological discovery toward diagnosis, prevention and treatment rather than offer general molecular observation alone. The editorial office sets separate length ceilings for research articles, reviews and systematic reviews, perspectives and correspondence, and draws on fields positioned along the translation chain. Its principal subject areas include:本刊的取稿立场是「以转化为尺度」，即要求研究须直接考察精神疾病本身并推动生物学发现向诊断、预防与治疗的转化，而非仅在分子层面作一般性观察。编辑部把研究论文、综述与系统综述、观点文章与通信四类稿件分设篇幅上限，并按转化链条上的位置分域收稿。收文覆盖的主要方向包括：

• Biomarker development: genetic, imaging, biochemical and electrophysiological markers of psychiatric disorders, and their translation into diagnostic aid and treatment stratification.生物标志物开发： 精神疾病的遗传、影像、生化与电生理标志物，及其向辅助诊断与分层治疗的转化。
• Preclinical models: animal and cellular models with clear clinical implications, used to test disease mechanisms and candidate interventions.临床前模型： 具清晰临床意义的动物与细胞模型，用以检验疾病机制与候选干预手段。
• Experimental medicine and mechanistic human studies: pharmacological, physiological and psychological studies in humans, including the dissection of mechanisms behind stimulation and behavioural interventions.实验医学与人体机制研究： 人体层面的药理、生理与心理机制研究，包括刺激与行为干预的机制拆解。
• Observational studies and clinical trials: cohort, case-control and interventional studies connecting biology to improved diagnosis, prevention and treatment.观察性研究与临床试验： 将生物学与更优诊断、预防和治疗相衔接的队列、病例对照与干预性试验。
• Supporting disciplines: genetics, pharmacology, epidemiology and neuroimaging, admitted where they bear explicit translational potential for psychiatric disorders.相关支撑学科： 遗传学、药理学、流行病学与神经影像等，须对精神疾病具备明确的转化潜力。

The journal enforces hard limits on article type and length. Research articles carry abstracts of 150 to 250 words, bodies of up to 5,000 words, at most six figures or tables and no more than 100 references. Reviews and systematic reviews run to 6,000 words and 250 references, with systematic reviews requiring a PRISMA 2020 checklist and flow diagram, while perspectives are capped at 4,000 words and correspondence at 1,000. Manuscripts are submitted through the publisher's own manuscript tracking system, and there is no pre-submission enquiry stage.期刊对体裁与篇幅设硬上限：研究论文摘要 150 至 250 词、正文不超过 5000 词、图表不超过 6 幅、参考文献不超过 100 条；综述与系统综述不超过 6000 词、参考文献不超过 250 条，其中系统综述须附 PRISMA 2020 清单与流程图；观点文章不超过 4000 词，通信不超过 1000 词。稿件经出版方自有的稿件跟踪系统投递，官方不设投稿前询问环节。

History

• Founding (2011): the journal published its first volume in April 2011 and has been electronic-only since launch, with no print edition. The serial number authority records the place of first publication as New York in the United States, while the present publisher is registered in London.创刊（2011年）： 本刊于 2011 年 4 月出版第 1 卷，自创刊起即为纯电子刊，没有印刷版；权威刊号记录将其创刊出版地著录为美国纽约，现行出版方注册地在英国伦敦。^[1]
• Rationale for founding: the journal arose from a long-standing break in the translational pipeline of psychiatry, a widening gap between the explosion of neuroscience and the therapeutic toolkit. The official account uses the example of Axelrod's 1961 discovery of monoamine reuptake, which still underpins antidepressants, to show how far that gap remains from closing.创刊动因： 创刊缘于精神病学的「转化管道」长期断裂，即神经科学的知识爆炸与治疗手段之间的落差持续拉大；官方以 1961 年阿克塞尔罗德发现单胺重摄取至今仍是抗抑郁药基础为例，说明这一落差尚未闭合。^[2]
• Publisher history: the journal was launched under the Nature Publishing Group name, and after that group's merger with Springer the official entity is now Springer Nature, with the title sitting in the Nature Portfolio. The former corporate name recorded in the library is discontinued.出版方沿革： 创刊时以 Nature Publishing Group 名义出版，后经该集团与 Springer 合并，现行官方主体为 Springer Nature，品牌归 Nature Portfolio；库内旧记的法人名已停用。^[3]
• Publication model: the journal publishes continuously, with articles appearing on acceptance and numbered consecutively within the volume. One volume still carries a year, the 2026 volume being the sixteenth, but discrete issue numbers are no longer assigned, which is why the serial number authority records the frequency as indeterminable.出版形态： 采用连续出版模式，论文录用即上线，卷内文章连续编号；每年仍编一个卷号，2026 年为第 16 卷，只是不再设分期号。官方刊号记录据此将刊期著录为无法确定的频率。^[1]
• Open access arrangements: the journal is fully open access, listed in the directory of open access journals, and defaults to the CC BY 4.0 licence. The publisher's current article processing charge is GBP 3,290, USD 4,990 or EUR 3,690 for original research, and GBP 950, USD 1,465 or EUR 1,185 for correspondence and commentary, with waivers available to corresponding authors in low-income countries.开放获取安排： 本刊完全开放获取，经开放获取期刊目录收录，默认采用 CC BY 4.0 许可；出版方现行文章处理费对原创研究为 3290 英镑、4990 美元或 3690 欧元，通信与评论类为 950 英镑、1465 美元或 1185 欧元，低收入国家通讯作者可申请减免。^[4]
• Metric trend: the impact factor rose from 4.691 in 2017 to 7.5 in 2025, with a five-year figure of 7.8, SNIP 1.811 and SJR 2.425. In the 2025 Chinese Academy of Sciences ranking it sits in the medical class 2 zone overall and in psychiatry at zone 2.指标走势： 影响因子自 2017 年的 4.691 波动上升至 2025 年的 7.5，五年影响因子 7.8，SNIP 1.811、SJR 2.425；2025 年在中科院分区中列于医学大类二区、小类精神病学二区。^[2]
• Review timeline: the publisher's official medians are 12 days from submission to first editorial decision and 261 days from submission to acceptance. The former includes editorial desk review and is pulled down heavily by manuscripts rejected without external review, so it should not be read as a measure of external review time. No acceptance rate is published.审稿口径： 出版方官方公布的中位时效为投稿至首次编辑决定 12 天、投稿至录用 261 天；前者包含编辑部桌审，这一极短数字主要由未经外审即退稿的稿件拉低，不等于外审周期。出版方不公布录用比例。^[2]
• Reach: its papers were downloaded more than 12.5 million times in 2025 and were mentioned over 6,300 times in Altmetric tracking, among the largest readership footprints of comparable open access psychiatry journals.传播规模： 2025 年该刊论文被下载逾一千二百五十万次，在 Altmetric 统计中被提及六千余次，是同类开放获取精神病学刊物中传播量级最大的之一。^[2]

Editors

The journal has had a single editor-in-chief since launch, which is unusual among Nature Portfolio titles. The editorial office comprises a managing editor and a number of associate editors, organised around the editor-in-chief's own academic orientation. Since that editor also founded three Nature titles, the editorial policy here stays closely aligned with its molecular-level sister journals.本刊自创刊起即由同一位主编连任，这在 Nature 系列刊物中较为少见；编辑部设管理编辑与若干副编辑，构成以主编学术取向为核心的组织形态。主编同时担任三份 Nature 系列刊物的创始主编，使该刊在编辑方针上与其分子层面的姊妹刊保持高度一致。

• Julio Licinio (founding editor-in-chief since 2011): distinguished professor at SUNY Upstate Medical University, trained in psychiatry, medicine, neuroscience and physiology. He is founding editor-in-chief of Molecular Psychiatry, Translational Psychiatry and The Pharmacogenomics Journal, and works on translational research in depression and obesity.胡里奥·利西尼奥（2011年起任，创始主编）： 纽约州立大学上州医学大学杰出教授，兼具精神病学、医学、神经科学与生理学训练，同时是 Molecular Psychiatry、Translational Psychiatry 与 The Pharmacogenomics Journal 的创始主编，研究方向为抑郁与肥胖的转化研究。^[5]
• Managing editor: Daniel Roche of the University of Maryland School of Medicine serves as managing editor, overseeing the day-to-day handling of manuscripts.管理编辑： 丹尼尔·罗什（Daniel Roche）任管理编辑，供职于马里兰大学医学院，负责日常稿件流程。^[5]
• Associate editor: Agorastos Agorastos serves as associate editor and is an associate professor of psychiatry at Aristotle University of Thessaloniki in Greece, working on post-traumatic stress disorder, the autonomic nervous system, the hypothalamic-pituitary-adrenal axis and circadian rhythms.副主编： 阿戈拉斯托斯·阿戈拉斯托斯（Agorastos Agorastos）任副主编，为希腊亚里士多德大学精神病学副教授，研究方向为创伤后应激障碍、自主神经系统、下丘脑—垂体—肾上腺轴与昼夜节律。^[5]
• Indexing: the journal is indexed in MEDLINE and PubMed, PubMed Central, Scopus, Web of Science, the directory of open access journals, the British Library and Crossref, a coverage consistent with its open access positioning.收录范围： 该刊被 MEDLINE 与 PubMed、PubMed Central、Scopus、Web of Science、开放获取期刊目录、大英图书馆与 Crossref 收录，索引覆盖面与其开放获取定位相符。^[2]
• Standing in the field: the journal is regarded as one of the flagship titles in translational psychiatry, its editorial principle of carrying biological discovery through to clinical application having been widely adopted by comparable journals, and it serves as a principal outlet through which biological psychiatry reaches practice.学科地位： 该刊被视为转化精神病学方向的旗舰刊物之一，其「从生物学发现到临床应用」的办刊口径已被同类刊物广泛沿用，是生物精神病学成果进入临床实践的主要发表出口。^[2]